However, the positive impact of metformin was primarily observed in hormone-receptor-positive patients, suggesting potential improvement in prognosis associated with diabetes and insulin treatment in HER2-positive and hormone-receptor-positive breast cancer patients. This evidence concerns the gene NR4A1 and breast cancer.